Grace Therapeutics (GRCE) Other Non Operating Income (2019 - 2026)
Grace Therapeutics (GRCE) posted Other Non Operating Income of -$5000.0 for Q1 2026, down 225.0% sequentially from $4000.0 in Q4 2025, and down 145.45% YoY from $11000.0 in Q1 2025.
Grace Therapeutics (GRCE) Other Non Operating Income (2019 - 2026) Analysis & Trends
Grace Therapeutics has reported Other Non Operating Income for 8 years, with the latest figure at -$5000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 145.45% year-over-year to -$5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1000.0 (changed N/A YoY) and the FY2024 annual result came in at -$16000.0, up 98.78% from the prior year.
- Other Non Operating Income slipped to -$5000.0 in Q1 2026 per GRCE's latest filing, from $4000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $13000.0 in Q3 2024 and troughed at -$1.2 million in Q1 2023.
- A 5-year average of -$94647.1 and a median of -$8000.0 in 2024 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income tumbled 633.33% in 2024, then soared 225.0% in 2025.
- Over 5 years, Other Non Operating Income stood at -$15000.0 in 2022, then jumped by 120.0% to $3000.0 in 2023, then sank by 633.33% to -$16000.0 in 2024, then soared by 125.0% to $4000.0 in 2025, then sank by 225.0% to -$5000.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$5000.0, $4000.0, and -$8000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -14,000.00 |
| Mar 31, 2026 | -5,000.00 |
| Dec 31, 2025 | 4,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Mar 31, 2025 | 11,000.00 |
| Dec 31, 2024 | -16,000.00 |
| Sep 30, 2024 | 13,000.00 |
| Jun 30, 2024 | -8,000.00 |
| Mar 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | -13,000.00 |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | -1.24 Mn |
| Dec 31, 2022 | -15,000.00 |
| Sep 30, 2022 | -12,000.00 |
| Jun 30, 2022 | -78,000.00 |
| Mar 31, 2022 | -249,000.00 |
| Dec 31, 2021 | -172,000.00 |
| Sep 30, 2021 | 1.10 Mn |